WO2008075369A3 - T-140 peptide analogs having cxcr4 super-agonist activity for bone marrow recovery - Google Patents

T-140 peptide analogs having cxcr4 super-agonist activity for bone marrow recovery Download PDF

Info

Publication number
WO2008075369A3
WO2008075369A3 PCT/IL2007/001596 IL2007001596W WO2008075369A3 WO 2008075369 A3 WO2008075369 A3 WO 2008075369A3 IL 2007001596 W IL2007001596 W IL 2007001596W WO 2008075369 A3 WO2008075369 A3 WO 2008075369A3
Authority
WO
WIPO (PCT)
Prior art keywords
bone marrow
agonist activity
peptide analogs
marrow recovery
cxcr4
Prior art date
Application number
PCT/IL2007/001596
Other languages
French (fr)
Other versions
WO2008075369A2 (en
Inventor
Amnon Peled
Michal Begin
Katia Beider
Michal Abraham
Original Assignee
Biokine Therapeutics Ltd
Amnon Peled
Michal Begin
Katia Beider
Michal Abraham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biokine Therapeutics Ltd, Amnon Peled, Michal Begin, Katia Beider, Michal Abraham filed Critical Biokine Therapeutics Ltd
Priority to EP07849622A priority Critical patent/EP2094274A4/en
Priority to CA2673719A priority patent/CA2673719C/en
Priority to US12/520,699 priority patent/US8455450B2/en
Priority to EP15169576.4A priority patent/EP3011961B1/en
Publication of WO2008075369A2 publication Critical patent/WO2008075369A2/en
Publication of WO2008075369A3 publication Critical patent/WO2008075369A3/en
Priority to IL199468A priority patent/IL199468A/en
Priority to IL218405A priority patent/IL218405A/en
Priority to US13/889,442 priority patent/US20140030211A1/en
Priority to IL244329A priority patent/IL244329B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention is directed to novel therapeutic uses of T- 140 analog peptides and compositions comprising same. Specifically, the invention provides compositions and methods useful for providing improved bone marrow transplantation and in the treatment of other conditions wherein bone marrow depletion or suppression is involved.
PCT/IL2007/001596 2006-12-21 2007-12-23 T-140 peptide analogs having cxcr4 super-agonist activity for bone marrow recovery WO2008075369A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
EP07849622A EP2094274A4 (en) 2006-12-21 2007-12-23 T-140 peptide analogs having cxcr4 super-agonist activity for bone marrow recovery
CA2673719A CA2673719C (en) 2006-12-21 2007-12-23 T-140 peptide analogs having cxcr4 super-agonist activity for bone marrow recovery
US12/520,699 US8455450B2 (en) 2006-12-21 2007-12-23 Methods for obtaining a therapeutically effective amount of hematopoietic precursor cells and long term engraftment thereof
EP15169576.4A EP3011961B1 (en) 2006-12-21 2007-12-23 4f-benzoyl-tn14003 for the mobilisation of hematopoietic progenitor cells in view of transplantation
IL199468A IL199468A (en) 2006-12-21 2009-06-21 T-140 peptide analogs having cxcr4 super-agonist activity for bone marrow recovery
IL218405A IL218405A (en) 2006-12-21 2012-02-29 T-140 peptide analogs having cxcr4 super-agonist activity for bone marrow recovery
US13/889,442 US20140030211A1 (en) 2006-12-21 2013-05-08 Methods for obtaining a therapeutically effective amount of hematopoietic precursor cells and long term engraftment thereof
IL244329A IL244329B (en) 2006-12-21 2016-02-28 T-140 peptide analogs having cxcr4 super-agonist activity for bone marrow recovery

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87614506P 2006-12-21 2006-12-21
US60/876,145 2006-12-21

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/520,699 A-371-Of-International US8455450B2 (en) 2006-12-21 2007-12-23 Methods for obtaining a therapeutically effective amount of hematopoietic precursor cells and long term engraftment thereof
US13/889,442 Division US20140030211A1 (en) 2006-12-21 2013-05-08 Methods for obtaining a therapeutically effective amount of hematopoietic precursor cells and long term engraftment thereof

Publications (2)

Publication Number Publication Date
WO2008075369A2 WO2008075369A2 (en) 2008-06-26
WO2008075369A3 true WO2008075369A3 (en) 2009-04-09

Family

ID=39536828

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/IL2007/001596 WO2008075369A2 (en) 2006-12-21 2007-12-23 T-140 peptide analogs having cxcr4 super-agonist activity for bone marrow recovery
PCT/IL2007/001598 WO2008075371A2 (en) 2006-12-21 2007-12-23 T-140 peptide analogs having cxcr4 super-agonist activity for immunomodulation
PCT/IL2007/001597 WO2008075370A2 (en) 2006-12-21 2007-12-23 T-140 peptide analogs having cxcr4 super-agonist activity for cancer therapy

Family Applications After (2)

Application Number Title Priority Date Filing Date
PCT/IL2007/001598 WO2008075371A2 (en) 2006-12-21 2007-12-23 T-140 peptide analogs having cxcr4 super-agonist activity for immunomodulation
PCT/IL2007/001597 WO2008075370A2 (en) 2006-12-21 2007-12-23 T-140 peptide analogs having cxcr4 super-agonist activity for cancer therapy

Country Status (7)

Country Link
US (5) US20100184694A1 (en)
EP (5) EP3011961B1 (en)
CA (2) CA2673719C (en)
ES (1) ES2842210T3 (en)
HK (1) HK1220899A1 (en)
IL (1) IL199468A (en)
WO (3) WO2008075369A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
AU2003261723A1 (en) 2002-08-27 2004-03-19 Takeda Chemical Industries, Ltd. Cxcr4 antagonist and use thereof
EP3011961B1 (en) * 2006-12-21 2020-11-11 Biokine Therapeutics LTD. 4f-benzoyl-tn14003 for the mobilisation of hematopoietic progenitor cells in view of transplantation
US9155780B2 (en) 2009-02-11 2015-10-13 Yeda Research And Development Co. Ltd. Short beta-defensin-derived peptides
MX2011013459A (en) * 2009-06-14 2012-05-08 Biokine Therapeutics Ltd Peptide therapy for increasing platelet levels.
WO2012058241A2 (en) 2010-10-26 2012-05-03 University Of South Alabama Methods and compositions for ameliorating pancreatic cancer
US20130303460A1 (en) * 2011-01-10 2013-11-14 Biokine Therapeutics Ltd. Peptides and compositions for the treatment of neuroectodermal derived tumors and retinoblastoma
US20140206629A1 (en) * 2011-02-17 2014-07-24 Rhode Island Hospital Stromal Derived Factor Inhibition And CXCR4 Blockade
TR201910409T4 (en) 2011-03-11 2019-08-21 Km Biologics Co Ltd Adjuvant composition containing citrulline.
WO2012129073A2 (en) * 2011-03-18 2012-09-27 University Of Virginia Patent Foundation Compositions and methods for tissue engineering and cell based therapies
EP2841084B1 (en) 2012-04-24 2018-05-30 Biokine Therapeutics Ltd. Cxcr4 antagonist peptide for use in the treatment of large cell lung cancer
WO2014021682A1 (en) * 2012-08-03 2014-02-06 가톨릭대학교 산학협력단 Cd11b+ cx3cr1+ cells, use thereof and method for mass collection of same
KR101419480B1 (en) * 2012-08-03 2014-07-14 가톨릭대학교 산학협력단 A method for mobilization of CD11b+CX3CR1+ cells
WO2016185476A1 (en) * 2015-05-20 2016-11-24 Biokine Therapeutics Ltd. Methods of obtaining mononuclear blood cells and uses thereof
EP3322431A2 (en) 2015-07-16 2018-05-23 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
US20180221393A1 (en) 2015-08-03 2018-08-09 Biokine Therapeutics Ltd. Cxcr4 binding agents for treatment of diseases
EP3368904A1 (en) * 2015-10-30 2018-09-05 Oxford University Innovation Ltd. Peptide and biomarker associated with inflammatory disorders, and uses thereof
AU2017222495B2 (en) 2016-02-23 2019-08-08 Biolinerx Ltd. Methods of treating acute myeloid leukemia
EP3709917A4 (en) 2017-11-17 2021-07-28 CryoConcepts LP Portable electro-mechanical cryosurgical device
BR112021008797A2 (en) * 2018-11-09 2021-08-31 Neopep Pharma Gmbh & Co. Kg POLYPEPTIDES FOR THE TREATMENT OF STRESS, IMMUNORECTION, AND STROKE SYNDROMES
EP4043041A1 (en) 2021-02-15 2022-08-17 Technische Universität München Cxcr4-ligands for diagnostic and therapeutic use and precursors thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060008465A1 (en) * 1998-10-05 2006-01-12 Pharmexa A/S Novel methods for therapeutic vaccination

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US5206018A (en) 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US4342828A (en) 1979-07-20 1982-08-03 Morinaga Milk Industry Co., Ltd. Method for producing substance capable of stimulating differentiation and proliferation of human granulopoietic stem cells
JPS61227526A (en) 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd Novel csf and method of collecting same
WO1986004605A1 (en) 1985-02-08 1986-08-14 Chugai Seiyaku Kabushiki Kaisha Human granulocyte colony stimulating factor
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
EP1186663A1 (en) 1985-08-23 2002-03-13 Kirin-Amgen, Inc. Production of pluripotent granulocyte colony-stimulating factor
ATE67517T1 (en) 1985-09-30 1991-10-15 Chugai Pharmaceutical Co Ltd HUMAN GRANULOCYTE COLONY STIMULATING FACTOR.
JPH0618778B2 (en) 1985-10-04 1994-03-16 中外製薬株式会社 Leukopenia treatment
EP0231819B1 (en) 1986-01-22 1992-04-01 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical agent for the treatment of myelogenous leukemia
ES2039209T5 (en) 1986-01-22 1996-07-16 Chugai Pharmaceutical Co Ltd PHARMACEUTICAL COMPOUND THAT PROMOTES THE RESTORATION OF HEMOPOYETIC CAPACITY.
DK203187A (en) 1986-04-22 1987-10-23 Immunex Corp HUMAN G-CSF PROTEIN EXPRESSION
GR871067B (en) 1986-07-18 1987-11-19 Chugai Pharmaceutical Co Ltd Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor
JPH0725689B2 (en) 1986-10-07 1995-03-22 中外製薬株式会社 Sustained-release preparation containing granulocyte colony-stimulating factor
JP2618618B2 (en) 1988-03-04 1997-06-11 協和醗酵工業株式会社 Anti-G-CSF derivative, ND28 monoclonal antibody
DK174044B1 (en) 1986-12-23 2002-05-06 Kyowa Hakko Kogyo Kk Polypeptide derived from human granulocyte colony stimulating factor, and method of preparation thereof, DNA encoding said polypeptide, recombinant plasmid containing said DNA, and microorganisms containing said recombinant plasmid .......
CA1340810C (en) 1988-03-31 1999-11-02 Motoo Yamasaki Polypeptide derivatives of human granulocyte colony stimulating factor
ATE111921T1 (en) 1988-06-03 1994-10-15 Chugai Pharmaceutical Co Ltd HUMAN CRYSTALLINE GRANULOCYTE COLONY STIMULATION FACTOR AND ITS PRODUCTION.
US5202117A (en) 1988-08-24 1993-04-13 Koichiro Tsuji Method of treating thrombi with g-csf
US5218092A (en) 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
US5104651A (en) 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
DE68925966T2 (en) 1988-12-22 1996-08-29 Kirin Amgen Inc CHEMICALLY MODIFIED GRANULOCYTE COLONY EXCITING FACTOR
IL96477A0 (en) 1989-12-01 1991-08-16 Amgen Inc Megakaryocyte production
GB9107846D0 (en) 1990-04-30 1991-05-29 Ici Plc Polypeptides
EP0459516A1 (en) 1990-06-01 1991-12-04 Kirin-Amgen, Inc. Oral dosage form of biologically active proteins
JP3249147B2 (en) 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド Oral preparation containing bioactive protein
IE912365A1 (en) 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
US5250732A (en) 1991-07-18 1993-10-05 Genentech, Inc. Ketamine analogues for treatment of thrombocytopenia
FR2686900B1 (en) 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa NOVEL POLYPEPTIDES HAVING GRANULOCYTE COLONY STIMULATION ACTIVITY, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
WO1995010534A1 (en) 1993-10-14 1995-04-20 Seikagaku Corporation Polypeptide and anti-hiv agent prepared therefrom
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5492126A (en) 1994-05-02 1996-02-20 Focal Surgery Probe for medical imaging and therapy using ultrasound
DE69840444D1 (en) 1997-05-23 2009-02-26 Prorhythm Inc DISMISSABLE FOCUSING ULTRASOUND APPLICATOR OF HIGH INTENSITY
US6569418B1 (en) 1997-12-11 2003-05-27 University Of Maryland Biotechnology Institute Immuno-modulating effects of chemokines in DNA vaccination
CA2245224A1 (en) 1998-08-14 2000-02-14 Jiang-Hong Giong Chemokine receptor antagonists and chemotherapeutics
WO2000009152A1 (en) 1998-08-14 2000-02-24 The University Of British Columbia Therapeutic chemokine receptor antagonists
CA2305787A1 (en) * 2000-05-09 2001-11-09 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
WO1999047158A2 (en) 1998-03-13 1999-09-23 The University Of British Columbia Therapeutic chemokine receptor antagonists
US6178522B1 (en) * 1998-06-02 2001-01-23 Alliedsignal Inc. Method and apparatus for managing redundant computer-based systems for fault tolerant computing
AU5241099A (en) 1998-07-31 2000-02-21 Trustees Of Columbia University In The City Of New York, The Use of inhibitors of the activation of cxcr4 receptor by sdf-1 in treating rheumatoid arthritis
US6576875B1 (en) * 1998-10-27 2003-06-10 Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E. V Method and device for controlling a targeted thermal deposition into a material
US20060079492A1 (en) 1999-10-25 2006-04-13 Ahlem Clarence N Compositions and treatment methods
US6365583B1 (en) 1999-02-02 2002-04-02 Anormed, Inc. Methods to enhance white blood cell count
GB9902399D0 (en) * 1999-02-03 1999-03-24 Smithkline Beecham Plc Compounds
ES2333399T3 (en) 1999-03-29 2010-02-22 Shire Canada Inc. METHODS TO TREAT A LEUKEMIA.
CA2389979C (en) 1999-11-24 2011-08-16 Schering Corporation Methods of inhibiting metastasis
AU2001236065A1 (en) 2000-03-03 2001-09-12 Nobutaka Fujii Antiviral compounds
JP2003532683A (en) 2000-05-09 2003-11-05 ザ ユニバーシティ オブ ブリティッシュ コロンビア CXCR4 antagonist treatment of hematopoietic cells
EP1323730B1 (en) 2000-09-05 2010-04-21 Biokine Therapeutics Ltd. Novel polypeptides and anti-hiv drugs containing the same
US8435939B2 (en) * 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
US20020159996A1 (en) 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US7630750B2 (en) 2001-02-05 2009-12-08 The Research Foundation For The State University Of New York Computer aided treatment planning
JP3374917B2 (en) 2001-02-16 2003-02-10 サンケン電気株式会社 Switching power supply
US7169750B2 (en) 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
US8774913B2 (en) 2002-04-08 2014-07-08 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for intravasculary-induced neuromodulation
AU2003261723A1 (en) * 2002-08-27 2004-03-19 Takeda Chemical Industries, Ltd. Cxcr4 antagonist and use thereof
DE10240064A1 (en) 2002-08-30 2004-03-11 Universitätsklinikum Freiburg Use of chemokine receptor antagonist for treatment of cancer and inhibition of metastasis, functions as ligand for the CXCR4 receptor
US7759336B2 (en) * 2002-12-10 2010-07-20 Ono Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic compounds and medicinal use thereof
US20050002939A1 (en) 2002-12-23 2005-01-06 Albert Zlotnik Tumor killing/tumor regression using CXCR4 antagonists
EP1608318A4 (en) 2003-03-27 2009-07-29 Univ Emory Cxcr4 antagonists and methods of their use
WO2004091518A2 (en) * 2003-04-11 2004-10-28 Anormed Inc. Cxcr4 chemokine receptor binding compounds
US8545463B2 (en) 2003-05-20 2013-10-01 Optimyst Systems Inc. Ophthalmic fluid reservoir assembly for use with an ophthalmic fluid delivery device
CN101444624B (en) 2004-03-19 2012-10-10 森永乳业株式会社 Medicine for cancer therapy
JP2008509928A (en) * 2004-08-13 2008-04-03 アノーメド インコーポレイテッド Chemokine combination to mobilize progenitor / stem cells
WO2006082588A2 (en) 2005-02-07 2006-08-10 Pharmalight Inc. Method and device for ophthalmic administration of active pharmaceutical ingredients
BRPI0615180A2 (en) * 2005-08-19 2011-05-03 Genzyme Corp method to intensify chemotherapy
CN101573441A (en) * 2005-12-08 2009-11-04 路易斯维尔大学研究基金会有限公司 Very small embryonic-like (vsel) stem cells and methods of isolating and using the same
EP2032691A2 (en) * 2006-06-15 2009-03-11 Neostem, Inc Processing procedure for peripheral blood stem cells
CN101495115A (en) 2006-08-02 2009-07-29 健赞股份有限公司 Combination therapy
WO2008016141A1 (en) * 2006-08-04 2008-02-07 Kurume University Kif-derived peptide capable of binding to hla-a24 molecule
EP3011961B1 (en) 2006-12-21 2020-11-11 Biokine Therapeutics LTD. 4f-benzoyl-tn14003 for the mobilisation of hematopoietic progenitor cells in view of transplantation
MX2011013459A (en) 2009-06-14 2012-05-08 Biokine Therapeutics Ltd Peptide therapy for increasing platelet levels.
CA2765188A1 (en) 2009-06-15 2010-12-23 Biokine Therapeutics Ltd. Novel chemokine binding polypeptides capable of inhibiting the course of autoimmunity, inflammation and cancer
US20130303460A1 (en) 2011-01-10 2013-11-14 Biokine Therapeutics Ltd. Peptides and compositions for the treatment of neuroectodermal derived tumors and retinoblastoma
EP2841084B1 (en) 2012-04-24 2018-05-30 Biokine Therapeutics Ltd. Cxcr4 antagonist peptide for use in the treatment of large cell lung cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060008465A1 (en) * 1998-10-05 2006-01-12 Pharmexa A/S Novel methods for therapeutic vaccination

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TAMAMURA, H. ET AL.: "T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer.", FEBS LETTERS., vol. 550, 30 July 2003 (2003-07-30), pages 79 - 83, XP004448372 *

Also Published As

Publication number Publication date
CA2673484A1 (en) 2008-06-26
EP3011961A1 (en) 2016-04-27
EP2104507A2 (en) 2009-09-30
US20100143334A1 (en) 2010-06-10
CA2673719A1 (en) 2008-06-26
WO2008075370A3 (en) 2016-06-09
IL199468A (en) 2017-06-29
EP2759302A3 (en) 2014-11-05
US8663651B2 (en) 2014-03-04
EP2094274A4 (en) 2011-05-11
US20100166715A1 (en) 2010-07-01
EP2094274A2 (en) 2009-09-02
EP2104507A4 (en) 2011-05-25
EP3011961B1 (en) 2020-11-11
WO2008075370A2 (en) 2008-06-26
US20140030211A1 (en) 2014-01-30
US20100184694A1 (en) 2010-07-22
ES2842210T3 (en) 2021-07-13
WO2008075369A2 (en) 2008-06-26
EP2942059A1 (en) 2015-11-11
US8455450B2 (en) 2013-06-04
EP2759302A2 (en) 2014-07-30
CA2673719C (en) 2018-07-24
US20120207748A1 (en) 2012-08-16
HK1220899A1 (en) 2017-05-19
US8765683B2 (en) 2014-07-01
WO2008075371A3 (en) 2009-04-16
WO2008075371A2 (en) 2008-06-26

Similar Documents

Publication Publication Date Title
WO2008075369A3 (en) T-140 peptide analogs having cxcr4 super-agonist activity for bone marrow recovery
PH12019500644A1 (en) Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
MY158325A (en) Multitype peptide compositions and methods for treatment or prevention of human papillpmavirus infection
MX2011008000A (en) Cyclosporin analogues for preventing or treating hepatitis c infection.
WO2010034032A3 (en) Methods for preparing purified polypeptide compositions
MX2009012675A (en) Reconstituted surfactants having improved properties.
TN2011000558A1 (en) Improved reconstituted surfactant composition containing analogs of surfactant protein b (sp-b) and surfactant protein c (sp-c)
EP2528934A4 (en) Aromatic-cationic peptides and uses of same
EP3111974A3 (en) Cell preparations for extemporaneous use, useful for healing and rejuvenation in vivo
NZ602471A (en) Antagonists of activin-actriia and uses for increasing red blood cell levels
WO2009025760A3 (en) Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
MX2009010148A (en) Cyclic receptor-associated protein (rap) peptides.
WO2010146578A3 (en) Peptide therapy for increasing platelet levels
GB201001602D0 (en) Oligopeptidic compounds and uses therof
ATE427956T1 (en) CKROX PEPTIDES AND THEIR ANALOGUES FOR THE TREATMENT OF SKIN AGING
MX2010002769A (en) Recombinant preparation of selected bromelain fractions.
TN2009000099A1 (en) Reconstituted surfactants having improved properties
UA87494C2 (en) Azaindoles useful as inhibitors of jak and other protein kinases
WO2011087795A3 (en) Methods of using small compounds to enhance myeloid derived suppressor cell function for treating autoimmune diseases
ATE540971T1 (en) PROTEIN KINASE C INHIBITORS FOR PREVENTING INSULIN RESISTANCE AND TYPE 2 DIABETES
WO2009047513A3 (en) Antagonists of kisspeptin and uses thereof
MX2011007462A (en) Hylauronic acid containing compositions for treatment of wounds, scars, post-surgical adhesion formation.
WO2006130718A3 (en) Synthetic peptide inhibitors of thrombin
WO2007138382A3 (en) Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis
EP1765851A4 (en) Analog compounds of analgesic peptides derived from the venom of crotalus durissus terrificus snakes, their uses, compositions, methods of preparation and purification

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07849622

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007849622

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2673719

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12520699

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 218405

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 244329

Country of ref document: IL